3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 2'-<2-(4-nitrophenyl)ethyl diisopropylphosphoramidite> | 156046-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 2'-<2-(4-nitrophenyl)ethyl diisopropylphosphoramidite>
• 英文别名: 3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-{[2-(4-nitrophenyl)ethoxy]carbonyl}adenosine 2'-[2-(4-nitrophenyl)ethyl diisopropylphosphoramidite]；3'-deoxy-5'-O-monomethoxytrityl-6-N-[2-(4-nitrophenyl)ethoxycarbonyl]-adenosine 2'-[2-(4-nitrophenyl)ethyl-N,N-diisopropyl-phosphoramidite]；3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine 2'-[2-(4-nitrophenyl)ethyl N,N-diisopropylphosphoramidite]；2-(4-nitrophenyl)ethyl N-[9-[(2R,3R,5S)-3-[[di(propan-2-yl)amino]-[2-(4-nitrophenyl)ethoxy]phosphanyl]oxy-5-[[(4-methoxyphenyl)-diphenylmethoxy]methyl]oxolan-2-yl]purin-6-yl]carbamate
• CAS: 156046-19-4
• 化学式: C₅₃H₅₇N₈O₁₁P
• 分子量: 1013.06
• InChiKey: CVVHWSSNUZKFHA-CPCLSVFGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.8
• 重原子数：
  73
• 可旋转键数：
  22
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  223
• 氢给体数：
  1
• 氢受体数：
  15

反应信息

• 作为反应物：
  描述：

  3'-deoxy-N⁶,2'-O-bis[2-(p-nitrophenyl)ethoxicarbonyl]adenosine 、 3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 2'-<2-(4-nitrophenyl)ethyl diisopropylphosphoramidite> 在 四氮唑 、 碘 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 以47%的产率得到3'-deoxy-5'-O-(monomethoxytrityl)-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenylyl-<2'-> -> 5'>-3'-deoxy-N6,2'-O-bis<2-(4-nitrophenyl)ethoxycarbonyl>adenosine
  参考文献：
  名称：

  核苷酸。第XLIV部分。单体和三聚体虫草素-胆固醇共轭物的合成，表征和生物学活性以及对HIV-1复制的抑制作用†

  摘要：

  抗病毒活性3'-脱氧腺苷基-（2'-5'）-3'-脱氧腺苷基-（2'-5'）-3'-脱氧腺苷（cordycepin三聚体核心）在2'-或5'-末端修饰通过经由碳酸酯键（15）或琥珀酸酯连接子（16和27）附着胆固醇来改善细胞通透性。相应的单体结合物4，7，和21虫草素制备成模型物质，研究预期的保护基团的适用性-的单甲氧（MeOTr）时，（叔-丁基）二甲基甲硅烷基（tbds），以及消除β-的2-（4-硝基苯基）乙基（npe）和2-（4-硝基苯基）乙氧羰基（npeoc）基团–用于最后的脱保护步骤，而不会损害酯的酯键共轭三聚体。使用亚磷酰胺化学方法在溶液中进行合成。完全保护的三聚体缀合物13，14，和26通过元素分析，UV和以及所有中间体进行了表征1 H-NMR光谱。解块缀合物15，16，和27根据HPLC是纯粹的，并显示通过质谱正确组合物。比较生物学研究表明，虫草素胆固醇共轭三聚体16和27分

  DOI：

  10.1002/hlca.19940770707
• 作为产物：
  描述：

  1-氯-2-(4-硝基苯基)乙烷 在 四氮唑 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 17.58h， 生成 3'-deoxy-5'-O-(monomethoxytrityl)-N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine 2'-<2-(4-nitrophenyl)ethyl diisopropylphosphoramidite>
  参考文献：
  名称：

  核苷酸部分XL。修饰的2'–5'腺苷酸三聚体-潜在的抗病毒药的合成和表征†

  摘要：

  通过亚磷酰胺法合成了在各种糖部分的3'-OH位置带有（叔丁基）二甲基甲硅烷基（tbds）的2'-5'腺苷酸三聚体41-44。比较了（叔丁氧基）羰基（boc）和2-（4-硝基苯基）乙基磺酰基（npes）基团在3'- O- tbds残基附近用于2'-OH保护的用途。目标三聚体。对于其他功能位置，赞成使用2-（4-硝基苯基）乙基（npe）和2-（4-硝基苯基）乙氧基羰基（npeoc）保护基。

  DOI：

  10.1002/hlca.19940770104

文献信息

• Nucleotides. Part LIII. 6-Aminohexanoyl-linked conjugates of monomeric and trimeric cordycepin
  作者：Marita Wasner、Wolfgang Pfleiderer、Robert J. Suhadolnik、Susan E. Horvath、Ning Kon、Ming-Xu Guan、Earl E. Henderson、Martin E. Adelson

  DOI：10.1002/hlca.19970800405

  日期：1997.6.30

  To improve cell permeability, monomeric 3′-deoxyadenosine (cordycepin) and antivirally active trimeric 3′-deoxyadenylyl-(2′–5′)-3′-deoxyadenylyl-(2′–5′)-3′-deoxyadenosine (2′–5′)d3 (A-A-A); (cordycepin-trimer core) were modified at the 2′-O- or 5′-O-position by myristic, cholic, and folic acid = tetradecanoic, 3α, 7α, 12α -trihy-droxy-5β-cholan-24-oic, and N-4-[(2-amino-3,4-dihydro-4-oxopteridin

  为了提高细胞通透性，单体3'-脱氧腺苷（cordycepin）和抗病毒活性三聚体3'-脱氧腺苷基-（2'-5'）-3'-脱氧腺苷基-（2'-5'）-3'-脱氧腺苷（2' –5′）d 3（AAA）；（虫草素三聚体核心）在所述2'-修饰ø -或5'- ø由肉豆蔻酸，胆酸，和叶酸=十四烷，3α，7α位上，12α-trihy-羟基- 5β胆-24- ，和分别通过6-氨基六酰基间隔基连接的N- 4-[（（2-氨基-3,4-二氢-4-氧蝶呤-6-6基）甲基]氨基}苯甲酰基} -L-谷氨酸。三聚体的离析物的合成21，27，和28通过亚磷酰胺化学反应，使用β-消除的2-（4-硝基苯基）乙基（npe），2-（4-硝基苯基）乙氧基羰基（npeoc）和（9 H-芴-9-基）甲氧基羰基（fmoc）基团进行允许在非质子传递溶剂中用DBU进行脱保护而不会损害与酯结合的结合物，得到产物24 – 26和31 – 33
• Nucleotides. Part IL. Synthesis and Characterization of Cordycepin-Trimer-Vitamin and -Lipid Conjugates Potential Inhibitors of HIV-1 Replication
  作者：Marita Wasner、Wolfgang Pfleiderer、Robert J. Suhadolnik、Susan E. Horvath、Ning Kon、Ming-Xu Guan、Earl E. Henderson、Martin E. Adelson、Earl E. Henderson、Robert J. Suhadolnik

  DOI：10.1002/hlca.19960790305

  日期：1996.5.8

  that inhibit HIV-1-induced syncytia formation with IC50 values of 7, 18, and 24 m̈M for 39, 29, and 42, respectively, and inhibit HIV-1 reverse transcriptase (RT) activity from 14 to 96% (see Table). Of the nine conjugates tested, inhibition of HIV-1 replication by 28, 29, 32, 40, and 42 may be attributed in part to the activation of the RNase L/PKR antiviral pathways. Trimer conjugate 42 showed the greatest

  抗病毒活性3'-脱氧腺烯基-（2'-5'）-3'-脱氧腺烯基-（2'-5'的可生物降解的2'-和5'-酯和2'-和5'-碳酸酯结合物的合成首先通过制备获得具有维生素E，D 2和A以及脂质1,2-二-O-棕榈酰甘油和1,2-二-O-十六烷基甘油的）-3'-脱氧腺苷（cordycepin-三聚体核心）三聚体离析物19-21（方案1）。其次，这些物质通过琥珀酸酯或碳酸盐连接基与亲脂性残基缩合，然后通过β-消除npeoc和npe保护基团进行脱保护，并进行酸处理以进行去三苯甲基化反应，而不会分别损害酯和碳酸盐的功能（方案2）。代谢稳定的虫草素-三聚体的维生素和-脂质共轭物是一类新生物缀合物的抑制HIV-1的诱导的合胞体形成的IC 50个值的7，18，和24毫米为39，29，和42，分别和禁止HIV-1逆转录酶（RT）活性从14％上升到96％（请参阅表）。在测试的九种结合物中，HIV-1复制受到28、
• Nucleotides Part LXX
  作者：Ramamurthy Charubala、Wolfgang Pfleiderer、Robert J. Suhadolnik、Kathryn T. Iacono、Nicholas F. Muto、Joseph W. Homan、Camille Martinand-Mari、Susan E. Horvath、Earl E. Henderson、Amber Steele、Thomas J. Rogers

  DOI：10.1002/1522-2675(200208)85:8<2284::aid-hlca2284>3.0.co;2-e

  日期：2002.8

  The chemical syntheses of nuclease-resistant, nontoxic bioactive (2'-5')agonists, 3'-deoxyadenylyl-(2'-->5')3'-deoxyadenylyl-(2'-->5')-3'-deoxyadenylyl-(2'-->2")-9-[(2"-hydroxyethoxy)methyl]adenine (d(3)A-d(3)A-d(3)A-etherA; 36), 1-benzyl-3'-deoxyadenylyl-(2'-->5')-3'-deoxyadenylyl-(2'-->5')-3'-deoxyadenylyl-(2'-->2")-9-[2"-hydroxyethoxy)methyl]adenine (N-1-benzyl-d(3)A-d(3)A-d(3)A-etherA; 37), N-6-benzyl-3'-deoxyadenylyl-(2'-5')3'-deoxyadenylyl-(2'-->5')-3'-deoxyadenylyl-(2'-->2")-9-[(2"-hydroxyethoxy)methyl]adenine (N-6-benzyl-d(3)Ad(3)A-d(3)A-etherA; 38), N-6-benzyladenylyl-(2'-->5')-adenylyl-(2'-->5')-adenylyl-(2'-->2")-9-[(2"-hydroxyethoxy)methyl]adenine (N-6-benzyl-A-A-A-etherA; 39), as well as the biological activities of 37, 38, and already synthesized and published adenylyl-(2'-->5')-adenylyl-(2'-->5')-adenylyl-(2'-->2")-9-[(2"-hydroxyethoxy)methyl]adenine (A-A-A-etherA; 40), are described. The above (2'-5')A derivatives 37-40 inhibit HIV-1 replication as measured by inhibition of syncytia formation, HIV-1 reverse transcriptase activity, or HIV-1 p24-antigen expression, with no evidence of cytotoxicity. Oligonucleotides 37, 38, and 40 were taken up intact into T cells in culture of cytoplasmic concentrations sufficient to activate the latent endoribonuclease, RNase L. N-6-Benzyl-d(3)A-d(3)A-d(3)A-etherA (38) also exerts immunostimulatory effects by increasing expression of monocyte chemotactic protein-1 (MCP-1), and, thereby, competing with HIV-1 for binding to a critical HIV-coreceptor.
• Synthesis of Trimeric Cordycepin-Vitamin Conjugates as Improved Antiviral Agents
  作者：Marita Wasner、Wolfgang Pfleiderer

  DOI：10.1080/15257779508012544

  日期：1995.5.1

  The chemical syntheses of various cordycepin trimers carrying vitamin E,D-2 and A via a succinate linker at the 2'-O- and 5'-O-position are described. The conjugates were characterized by physical means and used for biological investigations.
• Nucleotides, Part LIX, Synthesis, Characterization, and Biological Activities of New Potential Antiviral Agents: (2′ - 5′)Adenylate Trimer Analogs Containing 3′-Deoxy-3′-(hexadecanoylamino)adenosine at the 2′-Terminus
  作者：Helga Schirmeister-Tichy、Kathryn T. Iacono、Nicholas F. Muto、Joseph W. Homan、Robert J. Suhadolnik、Wolfgang Pfleiderer

  DOI：10.1002/(sici)1522-2675(19990407)82:4<597::aid-hlca597>3.0.co;2-v

  日期：1999.4.7

  Based upon 3'-amino-3'-deoxyadenosine (15), its protected 3'-hexadecanoylamino derivative 22 was chosen as starting material for the synthesis of a series of new modified 2'-5'-adenylate trimers 33-36 as potential antiviral agents. All (2'-5')A trimer analogs 33-36 inhibit HIV-1 replication as measured by the inhibition of syncytia formation and inhibition of HIV-1 reverse transcriptase activity. Compound 34 inhibits HIV-1 reverse transcription by 100% and subsequently inhibits expression of HIV-1 p24. However, compound 35 acts differently, since it does not inhibit HIV-1 reverse transcription, HIV-1 integrase, or HIV-1 p24 expression. Therefore, 35 appears to exert its inhibitory effect at a later stage of HIV-1 replication, i.e., the budding process.